Novo Nordisk halved Ozempic's US cash price to $499 a month for self-payers

In August 2025, Novo Nordisk announced a sweeping price cut for Ozempic: the monthly cost for cash-paying US patients with Type 2 diabetes dropped from a list price of $997 — 'nearly $1,000' — to $499, for all strengths. Wegovy, its other semaglutide drug, was made available at the same cash price.

The program targets the uninsured and underinsured, who face the steepest out-of-pocket costs; most insured US diabetes patients already paid far less, usually just under $25 a month. More than 70,000 US pharmacies participate through partnerships with GoodRx and Novo's own cash-pay channel, NovoCare, including ordering online with home delivery.

The company framed the cut as access and safety policy — keeping patients away from 'potentially unsafe and unapproved knockoff alternatives', in the words of Dave Moore, EVP of US operations — but analysts read it as a proactive response to rival drug launches from Eli Lilly and ongoing political scrutiny of high US drug prices.

Markets reacted immediately: Novo Nordisk shares jumped nearly 5%, while GoodRx surged close to 40%. The cut came shortly after Wegovy received FDA approval as a liver-disease treatment, broadening its indications.

Shares jumped nearly 5% on the announcement; GoodRx surged close to 40%; the offer put $499 Ozempic within reach of self-pay patients at 70,000+ pharmacies.

The cash channel was where compounded semaglutide copies were winning — that was the segment to defend.

Insured patients were untouched: the cut only repriced the self-pay segment, limiting the revenue hit.

Distribution through 70,000 pharmacies plus NovoCare made the price real, not a coupon footnote.

Moving first on price also bought goodwill amid political scrutiny of drug pricing.

When knockoffs undercut you, cut the cash price yourself before the counterfeiters define what your product is worth.

The announcement lifted Novo Nordisk shares nearly 5% and GoodRx close to 40% on the day; the material records no follow-up volume or revenue figures.